Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05020236
Title MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Pfizer

multiple myeloma



Daratumumab + Dexamethasone + Pomalidomide

Daratumumab + Elranatamab

Age Groups: adult | senior
Covered Countries ITA | FRA | ESP | DEU | CAN | BEL | AUT

No variant requirements are available.